Cocaine and amphetamine elicit differential effects in rats with a unilateral injection of dopamine transporter antisense oligodeoxynucleotides

Neuroscience

Volumn 76, Issue 3, 1996, Pages 737-747

  Silvia, C P ^a,b   Jaber, M ^a   King, G R ^a   Ellinwood, E H ^a   Caron, M G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Icagen Inc   (United States)

Author keywords

amphetamine; antisense oligodeoxynucleotides; cocaine; dopamine transporter; psychostimulants; rotational behavior

Indexed keywords

AMPHETAMINE; ANTISENSE OLIGODEOXYNUCLEOTIDE; COCAINE; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINE UPTAKE; GENETIC TRANSFECTION; IN SITU HYBRIDIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

EID: 0030580557     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(96)00399-5     Document Type: Article

References (46)

1. 1. Albert P. R. and Morris S. J. (1994) Antisense knockouts: molecular scalpels for the dissection of signal transduction. Trends pharmac. Sci. 15, 250-254.
2. 2. Bourson A., Borroni E., Austin R. H., Monsma F. J. Jr and Sleight A. J. (1995) Determination of the role of the 5-HT6 receptor in rat brain: a study using antisense oligonucleotides. J. Pharmac. exp. Ther. 274, 173-180.
3. 3. Buck K. J. and Amara S. G. (1994) Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium. Proc. natn. Acad. Sci. U.S.A. 91, 12584-12588.
4. 4. Cadoni C., Pinna A., Russi G., Consolo S. and Di Chiara G. (1995) Role of vesicular dopamine in the in vivo stimulation of striatal dopamine transmission by amphetamine: evidence from microdialysis and fos immunohistochemistry. Neuroscience 65, 1027-1039.
5. 5. Cerruti C., Pilotte N. S., Uhl G. and Kuhar M. J. (1994) Reduction in dopamine transporter mRNA after cessation of repeated cocaine administration. Brain Res. molec. Brain Res. 22, 132-138.
6. 6. Ciliax B. J., Heilman C., Demchyshyn L. L., Pristupa Z. B., Ince E., Hersch S. M., Niznik H. B. and Levey A. I. (1995) The dopamine transporter: immunochemical characterization and localization in brain. J. Neurosci. 15, 1714-1723.
7. 7. Eshleman A. J., Henningsen A., Neve K. and Jenowsky A. (1994) Release of dopamine via the human transporter. Molec. Pharmac. 45, 312-316.
8. 8. Fischer J. F. and Cho A. K. (1979) Chemical release of DA from striatal homogenates: evidence for an exchange diffusion model. J. Pharmac. 25, 1039-1043.
9. 9. Giros B. and Caron M. G. (1993) Molecular characterization of the dopamine transporter. Trends Neurosci. 14, 43-49.
10. 10. Giros B., El Mestikawy S., Godinot N., Zheng K., Han H., Yang-Feng T. and Caron M. G. (1992) Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Molec. Pharmac. 42, 383-390.
11. 11. Giros B., El Mestikawy S., Bertrand L. and Caron M. G. (1991) Cloning and functional characterization of a cocaine-sensitive dopamine transporter. Fedn Eur. biochem. Socs Lett. 295, 149-154.
12. 12. Giros B., Wang Y.-M., Suter S., McLeskey S. B., Pifl C. and Caron M. G. (1994) Delineation of discrete domains for substrate, cocaine and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J. biol. Chem. 269, 15985-15988.
13. 12a. Giros B., Jaber M., Jones S. R., Wightman R. M. and Caron M. G. (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606-612.
14. 2+ dependence of the amphetamine, nomifensine, and LU 19-005 effect on in vivo dopamine transmission. Eur. J. Pharmac. 166, 261-269.
15. 14. Hurd Y. L. and Ungerstedt U. (1989) Cocaine: an in vivo microdialysis evaluation of its acute action of dopamine neurotransmission in rat striatum. Synapse 3, 48-54.
16. 15. Irvani M. M. and Kruk Z. L. (1995) Effects of amphetamine on carrier-mediated and electrically stimulated dopamine release in slices of rat caudate putamen and nucleus accumbens. J. Neurochem. 64, 1161-1167.
17. 16. Izzo N. J. and Colucci W. S. (1994) Regulation of alpha 1B-adrenergic receptor half-life: protein synthesis dependence and effect of norepinephrine. Am. J. Physiol. 266, C771-775.
18. 17. Jaber M., Cador M., Dumartin B., Normand E., Stinus L. and Bloch B. (1995) Acute and chronic amphetamine treatments differentially regulate mRNA levels and c-Fos immunoreactivity in striatal neurons. Neuroscience 65, 1041-1050.
19. 18. Jaber M., Normand E. and Bloch B. (1995) Effect of reserpine treatment on the preproenkephalin mRNA level in the rat striatum: an in situ hybridization study. Molec. Brain Res. 32, 156-160.
20. 19. Jaber M., Tison F., Fournier M. C. and Bloch B. (1994) Differential influence of haloperidol and sulpiride on dopamine receptors and peptide mRNA levels in the rat striatum and pituitary. Molec. Brain Res. 23, 14-20.
21. 20. Jones S. R., Garris P. A. and Wightman R. M. (1995) Different effects of cocaine and nomifensine on dopamine uptake in the caudate-putamen and nucleus accumbens. J. Pharmac. Exp. Ther. 274, 396-403.
22. 21. Kilty J. E., Lorang D. and Amara S. G. (1991) Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science 254, 578-579.
23. 22. Kitayama S., Shimada S., Xu H., Markham L., Donovan D. M. and Uhl G. R. (1992) Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc. natn. Acad. Sci. U.S.A. 89, 7782-7785.
24. 23. Knepper S. M., Grunewald G. L. and Rutledge C. O. (1988) Inhibition of norepinephrine transport into synaptic vesicles by amphetamine analogs. J. Pharmac. exp. Ther. 247, 487-494.
25. 24. Lucas J. J. and Hen R. (1995) New players in the 5-HT receptor field: genes and knockouts. Trends Neurosci. 16, 246-252.
26. 25. Mack F. and Bonish H. (1979) Dissociation constants and lipophilicity of catecholamines and related compounds. Naunyn-Schmiedeberg's Arch. Pharmac. 310, 1-9.
27. 26. Mackler S. A. and Eberwine J. H. (1991) The molecular biology of addictive drugs. Molec. Neurobiol. 5, 45-58.
28. 27. Miller H. H., Shore P. A. and Clarke D. E. (1980) In vivo monoamine oxidase inhibition by D-amphetamine. Biochem. Pharmac. 29, 1347-1354.
29. 27a. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates, 2nd edn. Academic, Sydney.
30. 28. Pifl C., Giros B. and Caron M. G. (1993) Dopamine transporter expression confers cytotoxicity to low doses of the Parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J. Neurosci. 13, 4246-4253.
31. 29. Pifl C., Drobny H., Reither H., Hornykiewicz O. and Singer E. A. (1995) Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Molec. Pharmac. 47, 368-373.
32. 30. Ritz M. C., Lamb R. J., Goldberg S. R. and Kuhar M. J. (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237, 1219-1223.
33. 31. Robinson T. E. and Becker J. B. (1986) Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. Rev. 11, 157-198.
34. 32. Rossetti Z. L., Pani L., Kuzmin A., Carboni S. and Gessa G. L. (1990) Dihydropyridine calcium antagonists prevent cocaine-but not amphetamine-induced dopamine release and motor activity in rats. Acta physiol. hung. 75 Suppl., 249-250.
35. 33. Shimada S., Kitayama S., Lin C. L., Patel A., Nanthakumar E., Gregor P., Kuhar M. and Uhl G. (1991) Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science 254, 56-578.
36. 2 autoreceptors in the motor actions of cocaine. Molec. Pharmac. 46, 51-57.
37. 35. Standifer K. M., Chien C. C., Wahlestedt C., Brown G. P. and Pasternak G. W. (1994) Selective loss of delta opioid analgesia and binding by antisense oligodeoxynucleotides to a delta opioid receptor. Neuron 12, 805-810.
38. 36. Sulzer D. and Rayport S. (1990) Amphetamine and other psychstimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron 5, 797-808.
39. 37. Sulzer D., Maidment N. T. and Rayport S. (1993) Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J. Neurochem. 60, 527-535.
40. 38. Sulzer D., Chen T.-K., Lau Y. Y., Kristensen H., Rayport S. and Ewing A. (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15, 4102-4108.
41. 39. Usdin T. B., Mezey E., Chen C., Brownstein M. J. and Hoffman B. J. (1991) Cloning of the cocaine-sensitive bovine dopamine transporter. Proc. natn. Acad. Sci. U.S.A. 88, 11168-11171.
42. 40. Wahelstadt C., Pich E. M., Koob G. F., Yee F. and Heilig M. (1993) Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligonucleotides. Science 259, 528-531.
43. 41. Weiss B., Zhou L.-W., Zhang S.-P. and Qin Z.-H. (1993) Antisense oligodeoxynucleotide inhibits D2 dopamine receptor-mediated behavior and D2 messenger RNA. Neuroscience 55, 607-612.
44. 3H)amphetamine with rat brain synaptosomes. II. Active transport. J. Pharmac. exp. Ther. 257, 830-835.
45. 43. Zhang M. and Creese I. (1993) Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behavioral correlates. Neurosci. Lett. 161, 223-226.
46. 44. Zhang S. P., Zhou L. W. and Weiss B. (1994) Oligodeoxynucleotide antisense to the D1 dopamine receptor mRNA inhibits D1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine. J. Pharmac. exp. Ther. 271, 1462-1470.